(Q33901914)

29 July 2017

1 reference

title

Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. (English)

1 reference

29 July 2017

Michel P Hermans

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

16 May 2011

1 reference

Diabetes and Vascular Disease Research

29 July 2017

published in

1 reference

29 July 2017

volume

8

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

180-189

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111407783

21 January 2018

Identifiers

DOI

10.1177/1479164111407783

1 reference

29 July 2017

1 reference